Compare Sanofi SA (SNY) vs Invesco Solar ETF (TAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Invesco Solar ETF — how do they compare? Sanofi SA trades at $43.38 (market cap $104.30B), while Invesco Solar ETF trades at $52.33. The key difference: Sanofi SA pays a 5.55% dividend while Invesco Solar ETF pays none, and Invesco Solar ETF is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| SNY | TAN | |
|---|---|---|
Market Cap | $104.30B | — |
Sector | Health | Sector/Thematic |
52-Week High | $52.34 | $73.95 |
52-Week Low | $41.33 | $36.62 |
Enterprise Value | $124.19B | — |
Dividend Yield | 5.55% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.62, up 0.32% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 outlook. Revenue for 2025 was $46.72B with net income of $7.81B, showing improved profitability. Analyst consensus is mixed with 44% Buy, 52% Hold, and 4% Sell ratings. Recent news highlights regulatory approvals for new drugs and pipeline developments under new CEO leadership.
The outlook for SNY is cautiously optimistic, driven by Dupixent's growth and new drug approvals, but faces risks from pipeline setbacks and competition. Earnings momentum and cost discipline support upside potential, though valuation multiples like a P/E of 23.27 may limit near-term gains. Key risks include biosimilar threats post-2031 and ongoing legal challenges. Institutional activity shows increased holdings, reflecting confidence in the company's strategic direction.
TAN (Invesco Solar ETF) trades at $52.33, up 0.91% with a bearish technical signal from moving averages. The solar ETF faces mixed sentiment as recent Trump administration tariffs on polysilicon imports provide potential tailwinds for U.S. solar manufacturers while regulatory uncertainty and high volatility (beta 1.41) persist. Technical indicators show neutral oscillators with key support at $50 and resistance at $53.
The solar sector outlook is bifurcated between policy-driven opportunities and fundamental challenges. Tariff protections could benefit domestic manufacturers, but high expense ratios (0.7%) and residential solar demand concerns create headwinds. Investment appeal depends on policy stability and the sector's ability to capitalize on growing energy demand from data centers and AI infrastructure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Invesco Solar ETF
TAN is a thematic ETF that tracks the MAC Global Solar Energy Index. It provides targeted exposure to the global solar industry, including manufacturers of solar panels, installers, and component suppliers like Enphase and First Solar.
Read more on TAN →
